MSC 2490484A

Drug Profile

MSC 2490484A

Alternative Names: M-3814; MSC-2490484A

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck KGaA
  • Class Antineoplastics
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Jul 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO)
  • 01 Jul 2015 Merck KGaA initiates enrolment in a phase I trial for Solid tumours (Late-stage disease) in Germany (NCT02516813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top